Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):971–981. doi: 10.1002/pds.1637

Table 1.

Drugs associated with QT prolongation/Torsade de pointes grouped according to major class1

Anti-infective Antipsychotic/psychiatric Cardiovascular Miscellaneous
Amantadine (2) antiviral Chlorpromazine (1) antipsychotic Amiodarone (1) antiarrhythmic Alfuzosin (2) alpha1-antagonist
Azithromycin (2) macrolide Clozapine (2) Bepridil (1) CCA2 Arsenic trioxide (1) anti-neoplastic
Clarithromycin (1) Droperidol (1) Disopyramide (1) antiarrhythmic Chloral hydrate (2) Sedative
Erythromycin (1) Haloperidol (1) Dofetilide (1) Felbamate (2) antiepileptic
Foscarnet (2) antiviral Lithium (2) mood stabilizing Flecainide (2) Fosphenytoin (2) antiepileptic
Gatifloxacin (2) quinolone Mesoridazone (1) antipsychotic Ibutilide (1) Indapamide (2) diuretic (thiazide)
Gemifloxacin (2) Paliperidone (2) Isradipine (2) CCA2 Levomethadyl (1) opiate agonist
Halofantrine (1) anti-malarial Pimozide (1) Moexipril/HCTZ (2) anti-hypertensive Methadone (1) opiate agonist
Hydroxychloroquine (1) anti-protazoal Quetiapine (2) Nicardipine (2) CCA2 Octreotide (2) somatostatin analogue
Levofloxacin (2) quinolone Risperidone (2) Procainamide (1) antiarrhythmic Perflutren liquid microspheres (2) Cardiac echo contrast agent
Moxifloxacin (2) Thioridazine (1) Qunidine (1)
Ofloxacin (2) Venlafaxine (1) antidepressant Ranolazine (2) Tacrolimus (2) immunosuppressant
Pentamidine (1) anti-protazoal Ziprasidone (2) antipsychotic Sotalol (1) Tamoxifen (2) estrogen antagonist
Sparfloxacin (1) quinolone Tizanidine (2) alpha2-agonist
Telithromycin (2) ketolide Anti-emetics Salmeterol (2) beta2-adrenergic agonist
Voriconazole (2) triazole Dolasetron (2) serotonin Sunitinib (2) anti-neoplastic
Granisetron (2) receptor Vardenafil (2) phosphodiesterase inhibitor
Odansetron (2) antagonist
1

Numbers in parentheses correspond to likelihood that the agent is associated with torsade de pointes according to the Center for Therapeutics and Research (CERT) (4) (accessed April 2008). A ranking of '1' denotes drugs that are generally accepted to have a risk of causing torsades de pointes while '2' denotes drugs that have reported association with torsades de pointes but for which substantial evidence is lacking. Drugs not availible in the US (i.e., astemizole, cisapride, domperidone, probucol, roxythromycin, terfenadine) are excluded.

2

CCA - Calcium channel antagonist

HHS Vulnerability Disclosure